statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for BIIB
 DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy
 View More Analyst Ratings...

The Analyst Landscape: 27 Takes On Biogen

A new report from Morgan Stanley finds that people using GLP-1 drugs among them Ozempic, Wegovy, Mounjaro, and Zepbound reduce their consumption of tobacco and alcohol while taking the...

Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup

These Analysts Revise Their Forecasts On Biogen After Q1 Results

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

 Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

Biogen Unusual Options Activity For April 18

Biogen Unusual Options Activity

Where Biogen Stands With Analysts

A closer look at one of the leaders in the global multiple sclerosis therapeutics marketRelated Stocks: BIIB, AZN, PFE, ABBV, MRK, XBI, IBB, SPY, LLY...

Biogen: Doubts About The Future

Tritonpoint Wealth LLC acquired a new position in Biogen Inc. (NASDAQ:BIIB - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC...

2,023 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by Tritonpoint Wealth LLC

Bankruptcy filings in the healthcare sector rose significantly over the last three years, rising from 25 in 2021 to 46 in 2022 and 79 in 2023, which was the highest level in five years, according to...

Essential drugmaker to sell, liquidate in Chapter 11 bankruptcy

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Watchers	18,543
52-Wk Low	$189.44
52-Wk High	$319.76

Volume	350.00
52-Wk High	$319.76
52-Wk Low	$189.44

Period	Estimated	Reported	Surprise	Result
Q2'24	$3.98	--	--	N/A
Q1'24	$3.45	$3.67	6.44%	BEAT
Q4'23	$3.18	$2.95	-7.35%	MISSED
Q3'23	$3.97	$4.36	9.73%	BEAT
Q2'23	$3.78	$4.02	6.45%	BEAT

BIIB Biogen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals